Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2026
Red blood cell alloimmunization in transfused oncology patients at a high-complexity center in Colombia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meza Jennifer Rodríguez, Ortiz Rojas Helen Johana, Ocampo Jessica Largo, Pérez Laura Marcela Cárdenas
Аннотация
BACKGROUND: Red blood cell transfusion is essential for managing anemia in cancer patients but can induce erythrocyte alloimmunization, particularly against Rh (anti-E) and Kell (anti-K) antigens, which complicates transfusion compatibility and increases the risk of hemolytic events. This study assessed the prevalence and profile of irregular antibodies in transfused oncology patients at a high-complexity center.
METHODS: A retrospective descriptive study analyzed medical records of 179 adult patients with solid tumors or hematologic neoplasms who received red blood cell transfusions. Demographic, clinical, and immunohematologic variables were analyzed. Irregular antibody detection was performed using gel agglutination (ID-Card LISS/Coombs) processed on the IH 500 analyzer. Statistical analysis was descriptive and bivariate, using Chi-square, Fisher's exact, or Wilcoxon tests, as appropriate.
RESULTS: Of the study population, 65.9% were female, with a median age was 61 years. Solid tumors predominated (73.7%). Blood group O (61.5%) and RhD positive status (83.8%) were most common. Among clinically significant alloantibodies, anti-E (26.3%) and anti-K (15.1%) were the most frequently identified specificities. In addition, autoantibodies were detected in 30.2% of patients and were significantly more common in patients with hematologic neoplasms (42.6% vs. 25.8%; p = 0.031). These patients also required more transfusions and crossmatches after a positive irregular antibody screen (IAS) (p < 0.001).
CONCLUSION: Alloimmunization is frequent in transfused oncology patients, primarily involving Rh and Kell systems, complicating compatible unit procurement. Antibodies against Duffy and Kidd systems add further challenges. Extended phenotyping for Rh and Kell could reduce alloimmunization risks and enhance transfusion safety in this population.
METHODS: A retrospective descriptive study analyzed medical records of 179 adult patients with solid tumors or hematologic neoplasms who received red blood cell transfusions. Demographic, clinical, and immunohematologic variables were analyzed. Irregular antibody detection was performed using gel agglutination (ID-Card LISS/Coombs) processed on the IH 500 analyzer. Statistical analysis was descriptive and bivariate, using Chi-square, Fisher's exact, or Wilcoxon tests, as appropriate.
RESULTS: Of the study population, 65.9% were female, with a median age was 61 years. Solid tumors predominated (73.7%). Blood group O (61.5%) and RhD positive status (83.8%) were most common. Among clinically significant alloantibodies, anti-E (26.3%) and anti-K (15.1%) were the most frequently identified specificities. In addition, autoantibodies were detected in 30.2% of patients and were significantly more common in patients with hematologic neoplasms (42.6% vs. 25.8%; p = 0.031). These patients also required more transfusions and crossmatches after a positive irregular antibody screen (IAS) (p < 0.001).
CONCLUSION: Alloimmunization is frequent in transfused oncology patients, primarily involving Rh and Kell systems, complicating compatible unit procurement. Antibodies against Duffy and Kidd systems add further challenges. Extended phenotyping for Rh and Kell could reduce alloimmunization risks and enhance transfusion safety in this population.